4[1]Tsuruo T,Iida H,Tsukagoshi S,et al.4'-O-tetrahydropyranyladriamycin as a potential new antitumor agent[J].Cancer Res,1982,42 (4):1462-1467.
5[7]Herait P,Poutignat N,Marty M,et al.Early assessment of a new anticancer drug analogue are the historical comparisons obsolete-The French Experience with Pirarubicin[J].Eur J Cancer,1992,28A:1670-1676.
6[8]Okuma K,Furuta I,Ota K.Acute cardiotoxicity of antharacyclines-analysis by using holter ECG[J].J Cancer Chemother,1984,11 (4):901-905.
7[9]Tsutsumi Y,Kawamura T,Saitoh S,et al.Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab:necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy[J].Leuk Lymphoma,2004,45 (3):627-629.
8[10]Law JK,Ho JK,Hoskins PJ,et al.Fatal reactivation of hepatitis B postchemotherapy for lymphoma in a hepatitis B surface antigen-negative,hepatitis B core antibody-positive patient:potential implications for future prophylaxis recommendations[J].Leuk Lymphoma,2005,46 (7):1085-1089.
9Maloney DG,Smith B,Rose A.Rituximab:mechanism of action and resistance[J].Semin Oncol,2002,29(1 Suppl 2) -2 -9.
10Pfreundschuh M,Tr(u)mper L,Kloess M,et al.Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas:results of the NHL-B2 trial of the DSHNHL[J].Blood,2004,104(3):634 -641.
